Current advances in nanodrug delivery systems for malaria prevention and treatment
Source abstract
Abstract
Abstract Malaria is a life-threatening, blood-borne disease with over two hundred million cases throughout the world and is more prevalent in Sub-Saharan Africa than anywhere else in the world. Over the years, several treatment agents have been developed for malaria; however, most of these active pharmaceutical ingredients exhibit poor aqueous solubility and low bioavailability and may result in drug-resistant parasites, thus increasing malaria cases and eventually, deaths. Factors such as these in therapeutics have led to a better appreciation of nanomaterials. The ability of nanomaterials to function as drug carriers with a high loading capacity and targeted drug delivery, good biocompatibility, and low toxicity renders them an appealing alternative to conventional therapy. Nanomaterials such as dendrimers and liposomes have been demonstrated to be capable of enhancing the efficacy of antimalarial drugs. This review discusses the recent development of nanomaterials and their benefits in drug delivery for the potential treatment of malaria.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Malaria Research and Control · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Gelband H, Bogoch II, Rodriguez PS, et al. Is malaria an important cause of death among adults? Am J Trop Med Hyg. 2020;103(1):41–7. https://doi.org/10.4269/ajtmh.20-0036.10.4269/ajtmh.20-0036 ↗
2. World Health Organization. World malaria report 2021. Geneva: World Health Organization; 2021.10.30875/6c551ba0-en ↗
3. Tuteja R. Malaria—an overview. FEBS J. 2007;274(18):4670–9.10.1111/j.1742-4658.2007.05997.x ↗
4. Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev. 2013;26(2):165–84. https://doi.org/10.1128/cmr.00079-12.10.1128/cmr.00079-12 ↗
5. McBride WJ. Chemoprophylaxis of tropical infectious diseases. Pharmaceuticals (Basel). 2010;3(5):1561–75. https://doi.org/10.3390/ph3051561.10.3390/ph3051561 ↗
6. Hyde JE. Drug-resistant malaria—an insight. FEBS J. 2007;274(18):4688–98.10.1111/j.1742-4658.2007.05999.x ↗
7. Moles E, Urbán P, Jiménez-Díaz MB, et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy. J Control Release. 2015;210:217–29. https://doi.org/10.1016/j.jconrel.2015.05.284.10.1016/j.jconrel.2015.05.284 ↗
8. Belete TM. Recent progress in the development of new antimalarial drugs with novel targets. Drug Des Dev Ther. 2020;14:3875–89. https://doi.org/10.2147/dddt.S265602.10.2147/dddt.S265602 ↗
9. Marcato PD. Pharmacokinetics and pharmacodynamics of nanomaterials. In: Durán N, Guterres SS, Alves OL, editors. Nanotoxicology. New York: Springer; 2014. p. 97–110.10.1007/978-1-4614-8993-1_4 ↗
10. Marques J, Valle-Delgado JJ, Urbán P, et al. Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery. Nanomedicine. 2017;13(2):515–25. https://doi.org/10.1016/j.nano.2016.09.010.10.1016/j.nano.2016.09.010 ↗
11. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. https://doi.org/10.1186/1556-276x-8-102.10.1186/1556-276x-8-102 ↗
12. Verma S, Singh S, Syan N, Mathur P, Valecha V. Nanoparticle vesicular systems: a versatile tool for drug delivery. J Chem Pharm Res. 2010;2(2):496–509.
13. Aderibigbe BA, Mhlwatika Z. Dual release kinetics of antimalarials from soy protein isolate-carbopol-polyacrylamide based hydrogels. J Appl Polym Sci. 2016;133(37):43918.10.1002/app.43918 ↗
14. Sailaja AK, Amareshwar P, Chakravarty P. Different techniques used for the preparation of nanoparticles using natural polymers and their application. Int J Pharm Pharm Sci. 2011;3(2):45–50.
15. Escobar-Chávez J, Rodríguez Cruz I, Domínguez-Delgado C, Díaz-Torres R, Revilla Vazquez A, Aléncaster N. Nanocarrier systems for transdermal drug delivery; 2012. p. 50.
16. Tiwari K, Bhattacharya S. The ascension of nanosponges as a drug delivery carrier: preparation, characterization, and applications. J Mater Sci Mater Med. 2022;33(3):28. https://doi.org/10.1007/s10856-022-06652-9.10.1007/s10856-022-06652-9 ↗
17. Iravani S, Varma RS. Nanosponges for drug delivery and cancer therapy: recent advances. Nanomaterials. 2022;12(14):2440.10.3390/nano12142440 ↗
18. Shakeel K, Raisuddin S, Ali S, et al. Development and in vitro/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery. J Liposome Res. 2019;29(1):35–43. https://doi.org/10.1080/08982104.2017.1410173.10.1080/08982104.2017.1410173 ↗
19. Thakkar M, Brijesh S. Physicochemical investigation and in vivo activity of anti-malarial drugs co-loaded in Tween 80 niosomes. J Liposome Res. 2018;28(4):315–21. https://doi.org/10.1080/08982104.2017.1376684.10.1080/08982104.2017.1376684 ↗
20. Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24. https://doi.org/10.1051/parasite/2018021. (Résistance de Plasmodium falciparum aux combinaisons thérapeutiques à base d’artémisinine : une épée de Damoclès sur les stratégies d’éradication du paludisme).10.1051/parasite/2018021 ↗
21. Jensen AR, Adams Y, Hviid L. Cerebral Plasmodium falciparum malaria: the role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunol Rev. 2020;293(1):230–52.10.1111/imr.12807 ↗
22. Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature. 2002;419(6906):520–6.10.1038/nature01107 ↗
23. Marchetti RV, Lehane AM, Shafik SH, Winterberg M, Martin RE, Kirk K. A lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparum. Nat Commun J. 2015;6:6721–8. https://doi.org/10.1038/ncomms7721.10.1038/ncomms7721 ↗
24. Pandey R, Zeeshan M, Ferguson D, et al. Real-time dynamics of Plasmodium NDC80 as a marker for the kinetochore during atypical mitosis and meiosis. bioRxiv; 2019.
25. Cheuka PM, Mayoka G, Okombo J, Chibale K. Chapter two-Medicinal chemistry progression of antimalarial hits from phenotypic whole cell screening of SoftFocus libraries. In: Chibale K, editor. Annual reports in medicinal chemistry. Academic Press; 2019. p. 25–71.
26. Langhorne J, Holder AA. Malaria. In: Delves PJ, editor. Encyclopedia of immunology. 2nd ed. Elsevier; 1998. p. 1658–63.10.1006/rwei.1999.0422 ↗
27. Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis. 2013;13(10):900–6. https://doi.org/10.1016/S1473-3099(13)70095-1.10.1016/S1473-3099(13)70095-1 ↗
28. Subramani PA, Vartak-Sharma N, Sreekumar S, et al. Plasmodium vivax liver stage assay platforms using Indian clinical isolates. Malar J. 2020;19(1):214. https://doi.org/10.1186/s12936-020-03284-8.10.1186/s12936-020-03284-8 ↗
29. Mordecai EA, Paaijmans KP, Johnson LR, et al. Optimal temperature for malaria transmission is dramatically lower than previously predicted. Ecol Lett. 2013;16(1):22–30. https://doi.org/10.1111/ele.12015.10.1111/ele.12015 ↗
30. Robert SW, Gilles HM. The epidemiology of malaria. In: Essential malariology. CRC Press; 2017.
31. Jawara M, Pinder M, Drakeley CJ, et al. Dry season ecology of Anopheles gambiae complex mosquitoes in The Gambia. Malar J. 2008;7(1):1–9.10.1186/1475-2875-7-156 ↗
32. Klein PW, Easterbrook JD, Lalime EN, Klein SL. Estrogen and progesterone affect responses to malaria infection in female C57BL/6 mice. Gend Med. 2008;5(4):423–33. https://doi.org/10.1016/j.genm.2008.10.001.10.1016/j.genm.2008.10.001 ↗
33. Krücken J Jr, Dkhil MA, Braun JV, et al. Testosterone suppresses protective responses of the liver to blood-stage malaria. Infect Immun. 2005;73(1):436–43.10.1128/IAI.73.1.436-443.2005 ↗
34. Muehlenbein MP, Alger J, Cogswell F, James M, Krogstad D. The reproductive endocrine response to Plasmodium vivax infection in Hondurans. Am J Trop Med Hyg. 2005;73(1):178–87.10.4269/ajtmh.2005.73.178 ↗
35. Esan A, Omisakin C, Titilayo O, Fasakin K. Evaluation of severity of malaria infection and effect of anti-malaria drugs on gender differences using blood cell lines parameters. Am J Med Sci Med. 2014;2(5):89–95.
36. Muawia AA, Nabiela ME. Effect of falciparum malaria on some plasma proteins in males: with special reference to the levels of testosterone and cortisol. Afr J Biochem Res. 2009;3(11):349–55.
37. Luzzatto L. Sickle cell anaemia and malaria. Mediterr J Hematol Infect Dis. 2012;4(1):e2012065.10.4084/mjhid.2012.065 ↗
38. Archer NM, Petersen N, Clark MA, Buckee CO, Childs LM, Duraisingh MT. Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition. Proc Natl Acad Sci. 2018;115(28):7350–5.10.1073/pnas.1804388115 ↗
39. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;415(6872):673–9.10.1038/415673a ↗
40. Lee W-C, Chin P-W, Lau Y-L, et al. Hyperparasitaemic human Plasmodium knowlesi infection with atypical morphology in peninsular Malaysia. Malar J. 2013;12(1):88. https://doi.org/10.1186/1475-2875-12-88.10.1186/1475-2875-12-88 ↗
41. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO; 2015.
42. Autino B, Corbett Y, Castelli F, Taramelli D. Pathogenesis of malaria in tissues and blood. Mediterr J Hematol Infect Dis. 2012;4(1):e2012061.10.4084/mjhid.2012.061 ↗
43. Grobusch MP, Kremsner PG. Uncomplicated malaria. Curr Top Microbiol Immunol. 2005;295:83–104.
44. Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93–129. https://doi.org/10.1016/j.cll.2009.10.001.10.1016/j.cll.2009.10.001 ↗
45. Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: severe malaria. Crit Care. 2003;7(4):315–23. https://doi.org/10.1186/cc2183.10.1186/cc2183 ↗
46. Okafor CN, Finnigan NA. Malaria (Plasmodium ovale). Treasure Island: StatPearls Publishing; 2020.
47. Hill SR, Thakur RK, Sharma GK. Antimalarial medications. Treasure Island (FL): StatPearls Publishing; 2022.
48. World Health Organization. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec. 2016;91(4):33–52.
49. Laurens MB. RTS, S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccin Immunother. 2020;16(3):480–9. https://doi.org/10.1080/21645515.2019.1669415.10.1080/21645515.2019.1669415 ↗
50. Casares S, Brumeanu T-D, Richie TL. The RTS, S malaria vaccine. Vaccine. 2010;28(31):4880–94.10.1016/j.vaccine.2010.05.033 ↗
51. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med. 2005;201(1):27–33. https://doi.org/10.1084/jem.20040989.10.1084/jem.20040989 ↗
52. Kurtovic L, Atre T, Feng G, et al. Multifunctional antibodies are induced by the RTS, S malaria vaccine and associated with protection in a phase 1/2a trial. J Infect Dis. 2021;224(7):1128–38.10.1093/infdis/jiaa144 ↗
53. Zavala F. RTS, S: the first malaria vaccine. J Clin Investig. 2022. https://doi.org/10.1172/jci156588.10.1172/jci156588 ↗
54. Almeida M, Vasconcelos M, Tarragô A, Mariúba L. Circumsporozoite surface protein-based malaria vaccines: a review. Rev Inst Med Trop Sao Paulo. 2021. https://doi.org/10.1590/s1678-9946202163011.10.1590/s1678-9946202163011 ↗
55. Plassmeyer ML, Reiter K, Shimp RL, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate*. J Biol Chem. 2009;284(39):26951–63. https://doi.org/10.1074/jbc.M109.013706.10.1074/jbc.M109.013706 ↗
56. Nielsen CM, Vekemans J, Lievens M, Kester KE, Regules JA, Ockenhouse CF. RTS, S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. Vaccine. 2018;36(12):1637–42. https://doi.org/10.1016/j.vaccine.2018.01.069.10.1016/j.vaccine.2018.01.069 ↗
57. Ballou WR, Cohen J. 53-Malaria vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: W.B. Saunders; 2013. p. 1133–7.10.1016/B978-1-4557-0090-5.00056-2 ↗
58. Keshavarz-Fathi M, Rezaei N. Chapter 3-Vaccines, adjuvants, and delivery systems. In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for cancer immunotherapy. Academic Press; 2019. p. 45–59.
59. Goto Y, Coler RN, Reed SG. Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun. 2007;75(2):846–51. https://doi.org/10.1128/iai.01205-06.10.1128/iai.01205-06 ↗
60. Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp). 2012;2(2):103–11. https://doi.org/10.1556/EuJMI.2.2012.2.2.10.1556/EuJMI.2.2012.2.2 ↗
61. Dunkelberger JR, Song W-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50. https://doi.org/10.1038/cr.2009.139.10.1038/cr.2009.139 ↗
62. Astill J, Wood RD, Sharif S. Chapter 83-Thrombocyte functions in the avian immune system. In: Kaspers B, Schat KA, Göbel TW, Vervelde L, editors. Avian immunology. 3rd ed. New York: Academic Press; 2022. p. 205–12.10.1016/B978-0-12-818708-1.00006-3 ↗
63. Loubens M, Vincensini L, Fernandes P, Briquet S, Marinach C, Silvie O. Plasmodium sporozoites on the move: switching from cell traversal to productive invasion of hepatocytes. Mol Microbiol. 2021;115(5):870–81. https://doi.org/10.1111/mmi.14645.10.1111/mmi.14645 ↗
64. Mancardi D, Daëron M. Fc receptors in immune responses. In: Reference module in biomedical sciences; 2014. https://doi.org/10.1016/B978-0-12-801238-3.00119-7.10.1016/B978-0-12-801238-3.00119-7 ↗
65. White MT, Verity R, Griffin JT, et al. Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15(12):1450–8. https://doi.org/10.1016/S1473-3099(15)00239-X.10.1016/S1473-3099(15)00239-X ↗
66. Rts S. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet. 2015;386(9988):31–45.10.1016/S0140-6736(15)60721-8 ↗
67. Guerra Mendoza Y, Garric E, Leach A, et al. Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 2019;15(10):2386–98. https://doi.org/10.1080/21645515.2019.1586040.10.1080/21645515.2019.1586040 ↗
68. Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645–50. https://doi.org/10.1016/j.vaccine.2013.12.011.10.1016/j.vaccine.2013.12.011 ↗
69. World Health Organization. Malaria: the malaria vaccine implementation programme (MVIP), 2023. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine-implementation-programme. Accessed Jan 2023.
70. Datoo MS, Natama MH, Somé A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397(10287):1809–18. https://doi.org/10.1016/s0140-6736(21)00943-0.10.1016/s0140-6736(21)00943-0 ↗
71. Moorthy V, Binka F. R21/Matrix-M: a second malaria vaccine? Lancet (London, England). 2021;397(10287):1782–3.10.1016/S0140-6736(21)01065-5 ↗
72. Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–33. https://doi.org/10.1007/s12026-018-8991-x.10.1007/s12026-018-8991-x ↗
73. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine. 2013;31(13):1725–33. https://doi.org/10.1016/j.vaccine.2013.01.039.10.1016/j.vaccine.2013.01.039 ↗
74. De Ridder S, Van der Kooy F, Verpoorte R. Artemisia annua as a self-reliant treatment for malaria in developing countries. J Ethnopharmacol. 2008;120(3):302–14.10.1016/j.jep.2008.09.017 ↗
75. Okebe J, Bojang K, D’Alessandro U. Use of artemisinin and its derivatives for the treatment of malaria in children. Pediatr Infect Dis J. 2014;33(5):522–4. https://doi.org/10.1097/inf.0000000000000306.10.1097/inf.0000000000000306 ↗
76. White NJ. 43-Malaria. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ, editors. Manson’s tropical infectious diseases. 23rd ed. Philadelphia: W.B. Saunders; 2014. p. 532- 600.e1.10.1016/B978-0-7020-5101-2.00044-3 ↗
77. Health Do. National guidelines for the treatment of malaria, South Africa 2019 2019.
78. Agrawal PK, Agrawal C, Blunden G. Artemisia extracts and artemisinin-based antimalarials for COVID-19 management: could these be effective antivirals for COVID-19 treatment? Molecules. 2022;27(12):3828.10.3390/molecules27123828 ↗
79. Mohandas N, An X. Malaria and human red blood cells. Med Microbiol Immunol. 2012;201(4):593–8. https://doi.org/10.1007/s00430-012-0272-z.10.1007/s00430-012-0272-z ↗
80. Elfawal MA, Towler MJ, Reich NG, Golenbock D, Weathers PJ, Rich SM. Dried whole plant Artemisia annua as an antimalarial therapy. PLoS ONE. 2012;7(12):e52746. https://doi.org/10.1371/journal.pone.0052746.10.1371/journal.pone.0052746 ↗
81. Nagaraj VA, Sundaram B, Varadarajan NM, et al. Malaria parasite-synthesized heme is essential in the mosquito and liver stages and complements host heme in the blood stages of infection. PLoS Pathog. 2013;9(8):e1003522. https://doi.org/10.1371/journal.ppat.1003522.10.1371/journal.ppat.1003522 ↗
82. John DT, Petri WA, editors. Markell and Voge’s medical parasitology. 9th ed. Philadelphia: WB Saunders; 2006. (Malaria).
83. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52(6):818–36. https://doi.org/10.2165/00003495-199652060-00004.10.2165/00003495-199652060-00004 ↗
84. Looareesuwan S, Oosterhuis B, Schilizzi BM, et al. Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria. Br J Clin Pharmacol. 2002;53(5):492–500. https://doi.org/10.1046/j.1365-2125.2002.01590.x.10.1046/j.1365-2125.2002.01590.x ↗
85. Afolabi BB, Okoromah CN. Intramuscular arteether for treating severe malaria. Cochrane Database Syst Rev. 2004;2004(4):Cd004391. https://doi.org/10.1002/14651858.CD004391.pub2.10.1002/14651858.CD004391.pub2 ↗
86. Tran T, Qiao Y, You H, Cheong DHJ. Chapter 25-Chronic inflammation in asthma: antimalarial drug artesunate as a therapeutic agent. In: Chatterjee S, Jungraithmayr W, Bagchi D, editors. Immunity and inflammation in health and disease. Academic Press; 2018. p. 309–18.10.1016/B978-0-12-805417-8.00025-1 ↗
87. Orrell C, Little F, Smith P, et al. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol. 2008;64(7):683–90. https://doi.org/10.1007/s00228-007-0452-8.10.1007/s00228-007-0452-8 ↗
88. Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem®). Malar J. 2009;8(1):S5. https://doi.org/10.1186/1475-2875-8-S1-S5.10.1186/1475-2875-8-S1-S5 ↗
89. Omari AA, Gamble C, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2006;2006(2):Cd005965. https://doi.org/10.1002/14651858.Cd005965.10.1002/14651858.Cd005965 ↗
90. Meshnick SR, Dobson MJ. The history of antimalarial drugs. In: Rosenthal PJ, editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. Humana Press; 2001. p. 15–25.10.1385/1-59259-111-6:15 ↗
91. Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144. https://doi.org/10.1186/1475-2875-10-144.10.1186/1475-2875-10-144 ↗
92. Mohammadi S, Jafari B, Asgharian P, Martorell M, Sharifi-Rad J. Medicinal plants used in the treatment of Malaria: a key emphasis to artemisia, cinchona, cryptolepis, and tabebuia genera. Phytother Res. 2020;34(7):1556–69. https://doi.org/10.1002/ptr.6628.10.1002/ptr.6628 ↗
93. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31(4):257–74. https://doi.org/10.2165/00003088-199631040-00003.10.2165/00003088-199631040-00003 ↗
94. Müller IB, Hyde JE. Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol. 2010;5(12):1857–73. https://doi.org/10.2217/fmb.10.136.10.2217/fmb.10.136 ↗
95. Visser BJ, Wieten RW, Kroon D, et al. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J. 2014;13(1):1–18.10.1186/1475-2875-13-463 ↗
96. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (London, England). 2005;366(9487):717–25.10.1016/S0140-6736(05)67176-0 ↗
97. Toden S, Goel A. The holy grail of curcumin and its efficacy in various diseases: is bioavailability truly a big concern? J Restor Med. 2017;6(1):27–36. https://doi.org/10.14200/jrm.2017.6.0101.10.14200/jrm.2017.6.0101 ↗
98. Cui L, Miao J, Cui L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother. 2007;51(2):488–94.10.1128/AAC.01238-06 ↗
99. Padmanaban G, Nagaraj VA, Rangarajan PN. Artemisinin-based combination with curcumin adds a new dimension to malaria therapy. Curr Sci. 2012;102:704–11.
100. Teng W-C, Kiat HH, Suwanarusk R, Koh H-L. Medicinal plants and malaria: applications, trends, and prospects, vol. 16. Boca Raton: CRC Press; 2016.10.1201/b19026 ↗